Archives by Month:
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- January 2024
- December 2023
- November 2023
- October 2023
- August 2023
- July 2023
- June 2023
- May 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- July 2016
- June 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- November 2012
- October 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- June 2009
- April 2009
- February 2009
- December 2008
- November 2008
- October 2008
- August 2008
- June 2008
- May 2008
Archives by Year:
Weighing The Week Ahead: How Stocks Can Ignore Political Turmoil
The economic calendar is normal with emphasis on inflation data and housing news. These routine reports continue in the background as the Washington headlines continue. We would all like to focus on markets, but the daily news flow emphasizes the turmoil. Many people are asking: How can markets ignore the political turmoil? Last Week Recap […]
Energy Infrastructure Needs A Catalyst
Last week we spent a couple of days with Catalyst Funds at their annual sales conference. Catalyst CEO Jerry Szilagyi has been a great partner for our MLP mutual fund, and we were asked to host eight roundtable discussions with the wholesalers who market it. We have developed many great relationships with them over the […]
3 ‘Strong Buy’ Biotechs That Can Double In 2018
Here are three stocks that analysts say are primed for huge out-sized growth in the next 12 months. Biotech stocks often present intriguing investment opportunities- although the rewards can be quickly eradicated if key regulatory approvals are delayed or refused. To minimize the risk, we specifically searched for stocks with a high degree of confidence from […]
Warnings Of A New Credit Crisis And The Potential For System Wide Bail-In Push
Alternative analysts are often shunned in their views that the ‘world is ending’ when it comes to the financial system, and this despite the fact that those who correctly forecast the bursting of the housing bubble and subsequent credit crisis were dead on in their assertions. But while many of these same prognosticators have so […]
AUD/USD Forecast Mar. 12-16
The Australian dollar managed to recover mostly thanks to hopes that the Trump tariffs are not so bad and despite not-so-great Australian data. Can it continue higher? Speeches by RBA members and an important Chinese figure stand out. Here are the highlights of the week and an updated technical analysis for AUD/USD. The Australian economy grew by […]
Above The 40 – Stock Market Returns To Its Originally Scheduled Program
AT40 = 48.5% of stocks are trading above their respective 40-day moving averages (DMAs)AT200 = 52.9% of stocks are trading above their respective 200DMAsVIX = 14.6 (11.5% drop)Short-term Trading Call: bullish Commentary The (expected) plunge in the volatility index, the VIX, says it all…the stock market is ready to return to its originally scheduled programming. The volatility index, […]
Anatomy Of Success: Nintendo (NTDOY)
When a company earns the coveted Zacks Rank #1 (Strong Buy), it is displaying the right characteristics to beat the market over the next one to three months. But of course, reaching this ideal rank is not an easy feat. Of the thousands of companies tracked by Zacks, only about 5% earn this designation. Below, […]
Trading Support And Resistance – March 11
This week we’ll begin with our monthly and weekly forecasts of the currency pairs worth watching. The first part of our forecast is based upon our research of the past 16 years of Forex prices, which show that the following methodologies have all produced profitable results: Trading the two currencies that are trending the most strongly over the […]
Why Investors Should Closely Watch The Oil Market
Oil’s price move in the upcoming weeks will be decisive for its overall performance in 2018. After our initial oil price target in 2018 was met recently, we published an oil price update where we mentioned that oil is not bearish, at least not from the long term perspective. Our outlook was based on the analysis of the […]
Investors Try On AI-based Drug Discovery With BioXcel
Last week BioXcel Therapeutics (Nasdaq: BTAI) went public at $11. It looks like a typical biotechnology company with two drugs (BXCL501 and BXCL701) in Phase 1/2 trials for mental disorders and cancer respectively. Both drugs look fairly promising based on the data presented and we’ll get to that. But BioXcel is taking a different approach to […]
